Journal of the Chinese Medical Association
Volume 69, Issue 6 , Pages 259-263, June 2006

Single-dose Sertaconazole Vaginal Tablet Treatment of Vulvovaginal Candidiasis

  • Peng-Hui Wang

      Affiliations

    • Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, National Yang-Ming University, Taipei, Taiwan, R.O.C.
    • Institute of Emergency and Critical Care Medicine, National Yang-Ming University, Taipei, Taiwan, R.O.C.
    • Corresponding Author InformationCorrespondence to: Dr. Peng-Hui Wang, Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan, R.O.C.
    • ,
  • Hsiang-Tai Chao

      Affiliations

    • Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, National Yang-Ming University, Taipei, Taiwan, R.O.C.
    • ,
  • Cheng-Li Chen

      Affiliations

    • Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan, R.O.C.
    • ,
  • Chiou-Chung Yuan

      Affiliations

    • Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, National Yang-Ming University, Taipei, Taiwan, R.O.C.

Received 30 September 2005; accepted 11 April 2006.

Background

Vulvovaginal candidiasis (VVC) is a bothersome disease in women. Poor compliance with the continuous use of antifungal vaginal drugs often results in treatment failure. The aim of the present study was to evaluate the efficacy, acceptability, and safety of single-dose sertaconazole vaginal tablet (500 mg) treatment compared with conventional 3-dose econazole vaginal tablet (150 mg) treatment for VVC.

Methods

In this open, randomized, and comparative study, 40 symptomatic patients with VVC confirmed by the smear method were enrolled. Patients in group A were treated with single-dose sertaconazole vaginal tablet and those in group B were treated continuously with econazole vaginal tablet for 3 days.

Results

The characteristics of the patients in both groups were comparable and without statistical difference. Group A showed a significantly better clearance rate for candidiasis than group B (100% vs. 72.2% on day 7, p = 0.013; 100% vs. 77.8% on day 14, p = 0.030), based on smear method results. Group A showed a more rapid response for symptom relief than group B on day 7, but there was no difference in overall symptom relief between group A and group B on day 14.

Conclusion

Single-dose sertaconazole proved to be a more convenient and symptom-relieving treatment for VVC. The advantages of such management are worthy of further study in women with relapse VVC.

Key Words:  econazole , sertaconazole , vulvovaginal candidiasis

No full text is available. To read the body of this article, please view the PDF online.

 

PII: S1726-4901(09)70253-9

doi:10.1016/S1726-4901(09)70253-9

Journal of the Chinese Medical Association
Volume 69, Issue 6 , Pages 259-263, June 2006

Article Tools